Friday, Aug 21, 2026
English News
  • Hyderabad
  • Telangana
  • AP News
  • India
  • World
  • Entertainment
  • Sport
  • Science and Tech
  • Business
  • Rewind
  • ...
    • NRI
    • View Point
    • cartoon
    • My Space
    • Education Today
    • Reviews
    • Property
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • My Space
  • Reviews
  • Education Today
  • Property
  • Lifestyle
Home | India | Who Approves Emergency Use Of Covovax

WHO approves emergency use of Covovax

New Delhi: The World Health Organisation on Friday approved emergency use listing of Covid vaccine Covovax, produced by the Serum Institute of India under licence from Novavax and part of the Covax facility portfolio. “This is yet another milestone in our fight against Covid-19. Covovax is now WHO approved for emergency use, showing excellent safety […]

By IANS
Updated On - 17 December 2021, 10:07 PM
WHO approves emergency use of Covovax
Representational Image
whatsapp facebook twitter telegram

New Delhi: The World Health Organisation on Friday approved emergency use listing of Covid vaccine Covovax, produced by the Serum Institute of India under licence from Novavax and part of the Covax facility portfolio.

“This is yet another milestone in our fight against Covid-19. Covovax is now WHO approved for emergency use, showing excellent safety and efficacy. Thank you all for a great collaboration,” Serum Institute of India CEO Adar Poonawala said.


Covovax has a two-dose regimen and is the ninth to receive emergency use approval from the WHO. However, it is yet to be granted emergency use authorisation (EUA) by the top drug regulator, the DCGI, in India.

The listing aims to increase access particularly in lower-income countries, 41 of which have still not been able to vaccinate 10 per cent of their populations, while 98 countries have not reached 40 per cent, said the global health body.

Covovax was assessed under the WHO EUL procedure based on the review of data on quality, safety and efficacy, a risk management plan, programmatic suitability, and manufacturing site inspections carried out by the Drugs Controller General of India.

The Technical Advisory Group for Emergency Use Listing (TAG-EUL), convened by the WHO and made up of experts from around the world, has determined that the vaccine meets WHO standards for protection against Covid-19, that the benefit of the vaccine far outweighs any risks, and that the vaccine can be used globally, the WHO said in a statement.

The Covovax vaccine, developed by the SII in partnership with the US-based Novavax, is the third India-related vaccines to be approved by the WHO. The other two vaccines are Covishield and Covaxin. Covaxin is India’s first indigenous Covid vaccines, while Covishield is Indian version of Britain’s AstraZeneca jab.


Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .


  • Follow Us :
  • Tags
  • Covovax
  • Novavax
  • Serum Institute of India (SII)
  • WHO

Related News

  • Congo’s Ebola outbreak becomes deadliest on record, kills over 2,300

    Congo’s Ebola outbreak becomes deadliest on record, kills over 2,300

  • Congo’s Ebola outbreak began months before official declaration: WHO

    Congo’s Ebola outbreak began months before official declaration: WHO

  • WHO classifies three widely used medicines, including a common BP drug, as Group 1 carcinogens

    WHO classifies three widely used medicines, including a common BP drug, as Group 1 carcinogens

  • Congo reports 930 Ebola deaths amid worsening outbreak

    Congo reports 930 Ebola deaths amid worsening outbreak

Latest News

  • Indian national declared bankrupt in Singapore over unpaid wages

    18 minutes ago
  • Amit Shah to attend SSB, border security programmes in Siliguri

    36 minutes ago
  • Aisha Wahab becomes first Afghan-American elected to US Congress

    50 minutes ago
  • Charter plane carrying eight crashes in western Alaska

    1 hour ago
  • NTA defends Rs 200 answer key challenge fee, says it benefits all candidates

    8 hours ago
  • Magnitude 6.7 earthquake strikes southern Peru; no damage reported

    8 hours ago
  • Iran accuses US of ‘economic war’ as Trump threatens tougher sanctions

    8 hours ago
  • Opinion: Section 22-A and Right to Property

    10 hours ago

company

  • Home
  • About Us
  • Contact Us
  • Privacy Policy

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

  • Telangana Today Telangana Today
Telangana Today Telangana Today

© Copyrights 2024 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam